XSpray Pharma AB - Asset Resilience Ratio
XSpray Pharma AB (XSPRAY) has an Asset Resilience Ratio of 0.42% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read XSPRAY total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2023)
This chart shows how XSpray Pharma AB's Asset Resilience Ratio has changed over time. See XSPRAY book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down XSpray Pharma AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of XSpray Pharma AB.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr3.10 Million | 0.42% |
| Total Liquid Assets | Skr3.10 Million | 0.42% |
Asset Resilience Insights
- Limited Liquidity: XSpray Pharma AB maintains only 0.42% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
XSpray Pharma AB Industry Peers by Asset Resilience Ratio
Compare XSpray Pharma AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for XSpray Pharma AB (2022–2023)
The table below shows the annual Asset Resilience Ratio data for XSpray Pharma AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.39% | Skr3.02 Million ≈ $324.57K |
Skr765.26 Million ≈ $82.35 Million |
+0.91pp |
| 2022-12-31 | -0.51% | Skr-3.00 Million ≈ $-322.74K |
Skr585.43 Million ≈ $63.00 Million |
-- |
About XSpray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the tr… Read more